Bioventus logo

Bioventus (BVS) Q3 2024 Earnings

BVS·Reported November 5, 2024·Before market open

Bioventus reported Q3 2024 revenue of $139.0M, missed analyst consensus of $144.8M by $5.9M. Diluted EPS came in at $0.06.

Revenue
$139.0Mmissed by $5.9M
Consensus: $144.8M
Diluted EPS
$0.06met estimate
Consensus: $0.06
SEC

SEC Filings

Earnings release8-K not filed yet

Financial Snapshot

Trailing eight quarters through Q3 2024

Net Income

View metric

Operating Cash Flow

View metric

EPS (Diluted)

View metric

Q3 2024 Earnings FAQ

Common questions about Bioventus's Q3 2024 earnings report.

Bioventus (BVS) reported Q3 2024 earnings on November 5, 2024 before market open.

Bioventus reported revenue of $139.0M and diluted EPS of $0.06 for Q3 2024.

Revenue missed the consensus estimate of $144.8M by $5.9M. EPS beat the consensus estimate of $0.06 by $0.00.

You can read the 10-Q periodic report (0001628280-24-045114) directly on SEC EDGAR. The filing index links above go to sec.gov.